Horizon Pharma CEO Timothy Walbert's 2018 pay jumps 617% to $17M

Horizon Pharma reports 2018 executive compensation

By ExecPay News

Published: March 18, 2020

Horizon Pharma reported fiscal year 2018 executive compensation information on March 18, 2020.
In 2018, seven executives at Horizon Pharma received on average a compensation package of $6.7M, a 374% increase compared to previous year.
Average pay of disclosed executives at Horizon Pharma
Timothy P. Walbert, Chief Executive Officer, received $17M in total, which increased by 617% compared to 2017. 81% of Walbert's compensation, or $14M, was in stock awards. Walbert also received $2M in non-equity incentive plan, $1.1M in salary, as well as $160K in other compensation.
For fiscal year 2018, the median employee pay was $207,196 at Horizon Pharma. Therefore, the ratio of Timothy P. Walbert's pay to the median employee pay was 81 to one.
Paul W. Hoelscher, Chief Financial Officer, received a compensation package of $7M, which increased by 656% compared to previous year. 83% of the compensation package, or $5.8M, was in stock awards.
Robert F. Carey, Executive Vice President, Chief Business Officer, earned $7M in 2018, a 662% increase compared to previous year.
Shao-Lee Lin, Chief Scientific Officer, received $7M in 2018.
Jeffrey W. Sherman, M.D., FACP, Chief Medical Officer, earned $3.7M in 2018.
Barry J. Moze, Chief Administrative Officer, received $2.7M in 2018, which increases by 180% compared to 2017.
Vikram Karnani, Executive Vice President, Chief Commercial Officer, earned $2.5M in 2018, a 230% increase compared to previous year.

Related executives

Vikram Karnani

Horizon Pharma

Executive Vice President, Chief Commercial Officer

Jeffrey FACP

Horizon Pharma

Chief Medical Officer

Timothy Walbert

Horizon Pharma

Chief Executive Officer

Paul Hoelscher

Horizon Pharma

Chief Financial Officer

Shao-Lee Lin

Horizon Pharma

Chief Scientific Officer

Robert Carey

Horizon Pharma

Former Executive Vice President, Chief Business Officer

Barry Moze

Horizon Pharma

Chief Administrative Officer

You may also like

Source: SEC filing on March 18, 2020.